Anonymized patient-level data from Alnylam available on the Vivli platform
“We are thrilled to welcome Alnylam as a member of Vivli,” said Rebecca Li, Vivli Executive Director. “Alnylam is showing its leadership by sharing its data using the Vivli platform.
Alnylam is leading the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options in a number of therapeutic areas.
“We are delighted to be able to share our clinical trial data with researchers through Vivli,” said Jenny Petersen, Director, Clinical Trial Disclosure and Transparency at Alnylam Pharmaceuticals. “We are proud we are able to take this step forward in our data sharing program as part of our ongoing data transparency commitments.”